Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease:

Slides:

Advertisements

Similar presentations

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Advertisements

Effect of fatty and lean fish intake on lipoprotein subclasses in subjects with coronary heart disease: A controlled trial Arja T. Erkkilä, PhD, Ursula.

The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes

Volume 26, Issue 2, Pages e2 (August 2017)

Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study Wang Ya, MD, Cheryl Reifer,

Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements

Wijtske Annema, PhD, Hendrik M

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps Kevin C. Maki, PhD,

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT) Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta- analysis and Systematic Review Shelley R. Salpeter, MD, Jacob S.

Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.

Volume 153, Issue 3, Pages e7 (September 2017)

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

An assessment by the Statin Liver Safety Task Force: 2014 update

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Omega-3 Fatty Acids for Cardioprotection

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial John J.P.

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Volume 153, Issue 3, Pages e7 (September 2017)

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men Gloria Lena Vega, PhD, Scott M. Grundy,

Adverse effects on insulin secretion of replacing saturated fat with refined carbohydrate but not with monounsaturated fat: A randomized controlled trial.

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial Erik S.G. Stroes, MD, PhD, Andrey.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results.

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C- III levels in patients from the MARINE and ANCHOR studies Christie.

Predictors of first-year statin medication discontinuation: A cohort study Heli Halava, MD, Risto Huupponen, MD, PhD, Jaana Pentti, BSc, Mika Kivimäki,

Fatty acid oxidation in normotriglyceridemic men

Effect of fatty and lean fish intake on lipoprotein subclasses in subjects with coronary heart disease: A controlled trial Arja T. Erkkilä, PhD, Ursula.

Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: A population-based study Tim Christen, MSc, Stella.

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis Robert Wolk, MD, PhD, DSc, Ehrin J.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial John J.P.

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo- controlled study Patrick M. Moriarty, MD, Eli M. Roth, MD, Adam.

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

Meredith Kilgore, PhD, Paul Muntner, PhD, J

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial James D. Otvos,

Levocetirizine and Prednisone Are Not Superior to Levocetirizine Alone for the Treatment of Acute Urticaria: A Randomized Double-Blind Clinical Trial

Comparative effects of an acute dose of fish oil on omega-3 fatty acid levels in red blood cells versus plasma: Implications for clinical utility William.

An assessment by the Statin Intolerance Panel: 2014 update

Task-sharing interventions for cardiovascular risk reduction and lipid outcomes in low- and middle-income countries: A systematic review and meta-analysis

Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial Jill.

Extended-Release Niacin/Laropiprant Lowers Serum Phosphorus Concentrations in Patients with Type 2 Diabetes and Mild Hyperphosphatemia Andrew G. Bostom,

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study Dirk J. Blom, MD, PhD, Louis O'Dea, MD, Andres Digenio, MD, PhD,

Higher triglyceride level predicts hyperuricemia: A prospective study of 6-year follow-up Yuan Zhang, Fengjiang Wei, PhD, Chen Chen, MD, Chunyou Cai,

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Chan Wah Kheong, Nik Raihan Nik Mustapha, Sanjiv Mahadeva

The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis Moritz C. Wyler von Ballmoos, MD, MPH, Bernhard.

Volume 154, Issue 5, Pages (November 2018)

Volume 26, Issue 2, Pages e2 (August 2017)

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia Raul D. Santos, Frederick J. Raal,

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT.

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review Ilse K. Luirink, MD, Jim.

Medical Treatment of Overactive Bladder: In Response

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

The Economic Burden of Hyponatremia: Systematic Review and Meta-Analysis Giovanni Corona, MD, PhD, Corinna Giuliani, MD, Gabriele Parenti, MD, PhD, Giorgio.

Effects of metformin in adolescents with polycystic ovary syndrome undertaking lifestyle therapy: a pilot randomized double-blind study Gwinnett Ladson,

Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia Anna.

Presentation transcript:

Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study Jan Oscarsson, MD, Kristina Önnerhag, MD, Ulf Risérus, MD, Mattias Sundén, PhD, Lars Johansson, MD, Per-Anders Jansson, MD, Linda Moris, MD, Peter M. Nilsson, MD, Jan W. Eriksson, MD, Lars Lind, MD Journal of Clinical Lipidology Volume 12, Issue 6, Pages 1390-1403.e4 (November 2018) DOI: 10.1016/j.jacl.2018.08.003 Copyright © 2018 National Lipid Association Terms and Conditions

Figure 1 Consolidated Standards of Reporting Trials (CONSORT) flow chart. AE, adverse event; OM-3CA, omega-3 carboxylic acids. Journal of Clinical Lipidology 2018 12, 1390-1403.e4DOI: (10.1016/j.jacl.2018.08.003) Copyright © 2018 National Lipid Association Terms and Conditions

Figure 2 Effects of OM-3CA and fenofibrate on (A) PDFF in all patients, (B) PDFF in patients stratified by PNPLA3 genetic variant (C/C vs G/G + G/C), (C) total liver volume, (D) total liver fat volume, (E) pancreas volume, and (F) serum triglyceride levels. Data are descriptive GMR (95% CI) of post-treatment to baseline values. Numbers of patients with the different PNPLA3 genotypes: n = 12 (C/C) and n = 9 (G/G + G/C) in the placebo group, n = 16 (C/C) and n = 10 (G/G + G/C) in the fenofibrate group, and n = 12 (C/C) and n = 9 (G/G + G/C) in the OM-3CA group. ∗P < .05, mixed effects model. CI, confidence interval; GMR, geometric mean ratio; OM-3CA, omega-3 carboxylic acids; PDFF, proton density fat fraction; PNPLA3, patatin-like phospholipase domain-containing protein 3. Journal of Clinical Lipidology 2018 12, 1390-1403.e4DOI: (10.1016/j.jacl.2018.08.003) Copyright © 2018 National Lipid Association Terms and Conditions

Figure 3 Effects of OM-3CA and fenofibrate on plasma FGF21 levels. Data are descriptive GMR (95% CI) of post-treatment to baseline values. ∗P < .05, mixed effects model. CI, confidence interval; FGF21, fibroblast growth factor 21; GMR, geometric mean ratio; OM-3CA, omega-3 carboxylic acids. Journal of Clinical Lipidology 2018 12, 1390-1403.e4DOI: (10.1016/j.jacl.2018.08.003) Copyright © 2018 National Lipid Association Terms and Conditions